Patents Assigned to Genentech
  • AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20160090377
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: December 9, 2015
    Publication date: March 31, 2016
    Applicant: Genentech, Inc.
    Inventors: Steven P. Govek, Mehmet Kahraman, Nicholas D. Smith, Jeffrey H. Hager, Edna Chow Maneval
  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
    Publication number: 20160082120
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: September 23, 2015
    Publication date: March 24, 2016
    Applicant: GENENTECH, INC.
    Inventors: Andrew Polson, Shang-Fan Yu, Yu-Waye Chu, Michael Wenger
  • Anti-Ly6E antibodies and methods of use
    Patent number: 9290578
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: March 22, 2016
    Assignee: Genentech, Inc.
    Inventors: Jyoti Asundi, Ron Firestein, Paul Polakis, Chie Sakanaka, Peter Chang, Rayna Takaki Venook
  • Amorphous form of an AKT inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof
    Patent number: 9290458
    Abstract: Disclosed is (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one monohydrochloride, forms, formulations, pharmaceutical compositions, processes of manufacturing and methods of use thereof.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: March 22, 2016
    Assignee: GENENTECH, INC.
    Inventors: Paroma Chakravarty, Sanjeev Kothari, Francis Gosselin, Scott J. Savage, Jeffrey Stults
  • ANTHRACYCLINE DISULFIDE INTERMEDIATES, ANTIBODY-DRUG CONJUGATES AND METHODS
    Publication number: 20160074528
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to an anthracycline drug moiety via a disulfide linker, anthracycline disulfide intermediates, and methods of using the antibody-drug conjugates.
    Type: Application
    Filed: September 11, 2015
    Publication date: March 17, 2016
    Applicant: GENENTECH, INC.
    Inventors: John A. Flygare, Thomas H. Pillow
  • ISOFORM SPECIFIC ANTI-HER4 ANTIBODIES
    Publication number: 20160075798
    Abstract: Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.
    Type: Application
    Filed: November 19, 2015
    Publication date: March 17, 2016
    Applicants: UNIVERSITY OF TURKU, GENENTECH, INC.
    Inventors: Mark X. Sliwkowski, Klaus Elenius, Maija Hollmen
  • ANTI-CLL-1 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20160075787
    Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: September 11, 2015
    Publication date: March 17, 2016
    Applicant: GENENTECH, INC.
    Inventors: Bing Zheng, Andrew Polson, Cecilia Chiu, Wei-Ching Liang
  • ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES
    Publication number: 20160074529
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: November 19, 2015
    Publication date: March 17, 2016
    Applicant: GENENTECH, INC.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Anti-hemagglutinin antibodies and methods of use
    Patent number: 9284365
    Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: March 15, 2016
    Assignee: Genentech, Inc.
    Inventors: Min Xu, Mercedesz Balazs, Ning Chai, Nancy Chiang, Henry Chiu, Zhonghua Lin, Patrick Lupardus, Gerald R. Nakamura, Hyunjoo Park, Lee Swem
  • Protein formulation
    Patent number: 9283273
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 15, 2016
    Assignee: GENENTECH, INC.
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • Antibodies
    Patent number: 9284376
    Abstract: The present invention relates to the use of VEGF antagonists and a novel anti-?5?1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-?5?1 antibodies and methods of making and using them.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: March 15, 2016
    Assignee: Genentech, Inc.
    Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
  • Inhibition of angiogenesis
    Patent number: 9284369
    Abstract: The present invention relates generally to the inhibition of inflammatory cell-mediated angiogenesis. In particular, the invention concerns the prevention or treatment of tumor angiogenesis, and the inhibition of tumor development, using Bv8 antagonists, such as anti-Bv8 antibodies.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: March 15, 2016
    Assignee: Genentech, Inc.
    Inventors: Napoleon Ferrara, Farbod Shojaei, Xiumin Wu, Cuiling Zhong
  • THERAPEUTIC PROTEIN FORMULATIONS
    Publication number: 20160068607
    Abstract: The present invention generally concerns formulations having a pH that inhibits aspartyl isomerization at an Asp-Asp motif in a therapeutic protein contained in such a formulation.
    Type: Application
    Filed: November 20, 2015
    Publication date: March 10, 2016
    Applicant: GENENTECH, INC.
    Inventors: Bruce KABAKOFF, Daren NELSON, Jun OUYANG, Trevor Eli SWARTZ
  • IMMUNOGENIC MUTANT PEPTIDE SCREENING PLATFORM
    Publication number: 20160069895
    Abstract: The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions.
    Type: Application
    Filed: September 10, 2015
    Publication date: March 10, 2016
    Applicant: GENENTECH, INC.
    Inventors: Lelia DELAMARRE, Patrick LUPARDUS, Ira MELLMAN, Mahesh YADEV, Suchit JHUNJHUNWALA, Jennie LILL
  • Process for making amino acid compounds
    Patent number: 9278917
    Abstract: The invention provides new processes for making and purifying amino acid compounds, which are useful in the preparation of AKT inhibitors used in the treatment of diseases such as cancer, including the compound (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: March 8, 2016
    Assignee: Genentech, Inc.
    Inventor: Travis Remarchuk
  • Pyridyl inhibitors of hedgehog signalling
    Patent number: 9278961
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: March 8, 2016
    Assignees: GENENTECH, INC., CURIS, INC.
    Inventors: Janet L. Gunzner, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina, Michael F. T. Koehler
  • Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof
    Publication number: 20160060262
    Abstract: The invention provides novel compounds having the general formula: wherein X1 is N or N+O?, and one of X2, X3 and X4 is N or N+—O? and the remainder of X2, X3 and X4 is C. R2, R3, R4, R5, R6. A, B and Y are as described herein. Additionally compositions compounds of Formula I and methods of use are further described herein.
    Type: Application
    Filed: October 30, 2015
    Publication date: March 3, 2016
    Applicant: GENENTECH, INC.
    Inventors: Joseph P. Lyssikatos, Lewis J. Gazzard, Emily Hanan, Samuel S. Kintz, Hans Edward Purkey
  • ANTI-HER2 ANTIBODY VARIANTS
    Publication number: 20160060353
    Abstract: The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains
    Type: Application
    Filed: September 18, 2014
    Publication date: March 3, 2016
    Applicant: GENENTECH, INC.
    Inventors: Henry B. LOWMAN, Resi B. GERSTNER, Paul J. CARTER
  • PYRAZOLO COMPOUNDS AND USES THEREOF
    Publication number: 20160060267
    Abstract: Provided are compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the present composition in the treatment of various disorders.
    Type: Application
    Filed: March 13, 2014
    Publication date: March 3, 2016
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Steven F. Bellon, Victor S. Gehling, Jean-Christophe Harmange, Kwong Wah Lai, Jun Liang, Peter Dragovich, Dan Ortwine, Sharada Labadie, Birong Zhang, Jim Kiefer
  • Methods of inhibiting vascular endothelial growth factor activity
    Patent number: 9273113
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: March 1, 2016
    Assignee: GENENTECH, INC.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara